|
Mar 19
|
Fusion Rockets 97%, As Radiopharmaceuticals Space Sparks On $2 Billion AstraZeneca Takeover
|
|
Mar 19
|
Super Micro, XPeng, AstraZeneca: Trending tickers
|
|
Mar 19
|
Heard on the Street: Pharma Goes Radioactive as AstraZeneca Announces Fusion Deal
|
|
Mar 19
|
AstraZeneca buys Canadian cancer treatment firm for close to £2bn
|
|
Mar 19
|
AstraZeneca joins radiopharmaceutical deals spree with $2.4B buyout of Fusion
|
|
Mar 19
|
AstraZeneca bets on next-generation cancer therapy with $2 billion Fusion deal
|
|
Mar 19
|
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
|
|
Mar 5
|
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
|
|
Feb 26
|
Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect
|
|
Feb 26
|
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
|
|
Jan 16
|
Finding the Best Cheap Stocks Under $10 to Buy in 2024
|
|
Jan 16
|
What Makes Fusion Pharmaceuticals Inc. (FUSN) a Strong Momentum Stock: Buy Now?
|
|
Jan 16
|
Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?
|
|
Jan 15
|
Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use
|
|
Jan 10
|
How Fusion Pharmaceuticals (FUSN) Stock Stands Out in a Strong Industry
|
|
Jan 9
|
Does Fusion Pharmaceuticals Inc. (FUSN) Have the Potential to Rally 47.76% as Wall Street Analysts Expect?
|
|
Dec 28
|
Why Fusion Pharmaceuticals (FUSN) Stock Was Up 14% on Wednesday
|
|
Dec 27
|
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
|
|
Dec 27
|
Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls
|
|
Dec 20
|
4 Drug Stocks Rising More Than 40% in 2023 With Room to Grow
|